[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-neuroendocrine-tumor-pnet\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-neuroendocrine-tumor-pnet":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100588619",false,"NCT06943755","Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","A Phase 2\u002F3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors","STELLAR-311","Key Inclusion Criteria:\n\n* Histologically confirmed, locally advanced\u002Funresectable or metastatic, well-differentiated Grade 1, 2, or 3 NETs of pancreatic origin or extra-pancreatic origin.\n* Allowed prior lines of therapy, based on the site of NET and functional status.\n* Documented radiographic disease progression per RECIST 1.1, as assessed by the Investigator based on imaging assessments (computed tomography \\[CT\\] or magnetic resonance imaging \\[MRI\\]) within 12 months before randomization.\n* Measurable disease according to RECIST 1.1 as determined by the Investigator.\n* Archival tumor tissue is required, if available. If archival tumor tissue is not available, a fresh biopsy may be submitted if it can be safely and feasibly obtained. Every attempt should be made to provide tumor tissue.\n\nKey Exclusion Criteria:\n\n* Histologically confirmed neuroendocrine carcinomas (including small cell lung cancer), medullary thyroid cancer, pheochromocytoma, paraganglioma, Merkel cell carcinoma, and mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN).\n* Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mTOR) inhibitor.\n* Systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks before randomization.\n* Systemic radionuclide therapy within 6 weeks before randomization.\n* Radiation therapy for bone metastases within 2 weeks, any other radiation therapy, except as indicated above, within 4 weeks before randomization.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},440,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.",[27,28],"Pancreatic Neuroendocrine Tumor (pNET)","Extra-Pancreatic Neuroendocrine Tumor (epNET)",[30,31,32],"Metastatic Cancer","Locally Advanced Cancer","Neuroendocrine Tumor (NET)","RECRUITING","2026-04-15",{"date":36,"type":37},"2026-04-17","ACTUAL",{"date":39,"type":37},"2025-07-21",{"date":41,"type":20},"2029-06",{"name":43,"class":44},"Exelixis","INDUSTRY",80,""]